United States Patent Office Patented Nov
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Chemicals Used for Chemical Manufacturing Page 1 of 2
Chemicals used for Chemical Manufacturing Page 1 of 2 Acetic Acid (Glacial, 56%) Glycol Ether PMA Acetone Glycol Ether PNB Acrylic Acid Glycol Ether PNP Activated Carbon Glycol Ether TPM Adipic Acid Glycols Aloe Vera Grease Aluminum Stearate Gum Arabic Aluminum Sulfate Heat Transfer Fluids Amino Acid Heptane Ammonium Acetate Hexane Ammonium Bicarbonate Hydrazine Hydrate Ammonium Bifluoride Hydrochloric Acid (Muriatic) Ammonium Chloride Hydrogen Peroxide Ammonium Citrate Hydroquinone Ammonium Hydroxide Hydroxylamine Sulfate Ammonium Laureth Sulfate Ice Melter Ammonium Lauryl Sulfate Imidazole Ammonium Nitrate Isobutyl Acetate Ammonium Persulfate Isobutyl Alcohol Ammonium Silicofluoride Calcium Stearate Dipropylene Glycol Isopropanolamine Ammonium Sulfate Carboxymethylcellulose Disodium Phosphate Isopropyl Acetate Antifoams Caustic Potash D'Limonene Isopropyl Alcohol Antifreeze Caustic Soda (All Grades) Dodecylbenzene Sulfonic Acid Isopropyl Myristate Antimicrobials Caustic Soda (Beads, Prills) (DDBSA) Isopropyl Palmitate Antimony Oxide Cetyl Alcohol Dowfrost Itaconic Acid Aqua Ammonia Cetyl Palmitate Dowfrost HD Jojoba Oil Ascorbic Acid Chlorine, Granular Dowtherm SR-1 Keratin Barium Carbonate Chloroform Dowtherm 4000 Lactic Acid Barium Chloride Chromic Acid EDTA Lanolin Beeswax Citric Acid (Dry and Liquid) EDTA Plus Lauric Acid Bentonite Coal Epsom Salt Lauryl Alcohol Benzaldehyde Cocamide DEA Ethyl Acetate Lecithin Benzoic Acid Copper Nitrate Ethyl Alcohol (Denatured) Lime Benzyl Alcohol Copper Sulfate Ethylene Glycol Linoleic Acid Bicarbonate -
Purified Sea Salt with Magnesium Carbonate
Cargill® Food Processing Salts Purified Sea Saltwith Magnesium Carbonate Product Description Physical Information Purified Sea Salt with Magnesium Carbonate This material is a food grade, granular, white crystalline Purified Sea Salt with Magnesium Carbonate sodium chloride product manufactured under stringent PHYSICAL MIN TARGET MAX process control procedures. Cargill Sea Salts are made from Pacific Ocean sea salt, which is harvested from ponds NaCl (%) 99.7 99.96 100 near the San Francisco Bay. Ca & Mg as Ca (%) 0.003 Sulfate as SO4 (%) 0.01 Product Application Water Insolubles (%) 0.025 0.01 Bulk Density (#cu/ft) 69 74 84 This material is intended for table and cooking use, as well as direct application in foods manufactured by the various Bulk Density (g/l) 1105 1185 1345 food processing industries. This material contains Surface Moisture (%) 0.02 Magnesium Carbonate, which is added to improve caking Magnesium Carbonate (%) 0.5 resistance and flowability. PERCENT PARTICLE SIZE MIN TARGET MAX Product Certifications DISTRIBUTION (SCREENS) Sieve - USS 30 Mesh Retained 0 40 50 Cargill® Sea Salts meet USDA, FDA and Food Chemicals Codex for food use. Sieve - USS 40 Mesh Retained 34 Sieve - USS 50 Mesh Retained 16 Cargill® Sea Salts are certified Kosher for Passover (OU-P) SieveCargill - USS 70 Mesh® RetainedSea Salt 8 by the Orthodox Union. Sieve - Retained on Pan 0 1 10 Made with Sun, Wind and Time Allergen Status Harvesting sea salt from San Francisco Bay today is similar to the salt-making process that has been used for centuries. In accordance with the 2004 USA Food Allergen Labeling and Consumer Protection Act (FALCPA), no allergen declarations are required for this product. -
Potassium-Magnesium Citrate Is an Effective Prophylaxis Against Recurrent Calcium Oxalate Nephrolithiasis
0022-5347/97/1586-2069$03.00/0 JOURNAL OF UROLOGY Vol. 158,2069-2073, December 1997 Copyright Q 1997 by AMERICANUROLOGICAL ASS~CIATION, INC. Printed in U.S.A. POTASSIUM-MAGNESIUM CITRATE IS AN EFFECTIVE PROPHYLAXIS AGAINST RECURRENT CALCIUM OXALATE NEPHROLITHIASIS BRUCE ETTINGER,* CHARLES Y. C. PAK, JOHN T. CITRON, CARL THOMAS, BEVERLEY ADAMS-HIJET AND ARLINE VANGESSEL From the Diuision of Research, Kaiser Permanente Medical Care Program, Oakland, California, the Department of Mineral Metabolism, Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, Department of Medicine, Kaiser Permanente Medical Center, Walnut Creek, California, Department of Urology, Kaiser Permanente Medical Center, San Francisco, California, and Kaiser Foundation Research Institute, Kaiser Foundation Hospitals, Oakland, California ABSTRACT Purpose: We examined the efficacy of potassium-magnesium citrate in preventing recurrent calcium oxalate kidney calculi. Materials and Methods: We conducted a prospective double-blind study of 64 patients who were randomly assigned to receive placebo or potassium-magnesium citrate (42 mEq. potassium, 21 mEq. magnesium, and 63 mEq. citrate) daily for up to 3 years. Results. New calculi formed in 63.6%of subjects receiving placebo and in 12.9%of subjects receiving potassium-magnesiumcitrate. When compared with placebo, the relative risk of treat- ment failure for potassium-magnesium citrate was 0.16 (95%confidence interval 0.05 to 0.46). potassium-magnesium citrate had a statistically significant effect (relative risk 0.10,95%confi- dence interval 0.03 to 0.36) even after adjustment for possible confounders, including age, pretreatment calculous event rate and urinary biochemical abnormalities. -
Laxatives for the Management of Constipation in People Receiving Palliative Care (Review)
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Laxatives for the management of constipation in people receiving palliative care (Review) Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 5 http://www.thecochranelibrary.com Laxatives for the management of constipation in people receiving palliative care (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 4 METHODS ...................................... 4 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 Figure3. ..................................... 10 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 14 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 17 DATAANDANALYSES. 26 ADDITIONALTABLES. 26 APPENDICES ..................................... 28 WHAT’SNEW..................................... 35 HISTORY....................................... 35 CONTRIBUTIONSOFAUTHORS . 36 DECLARATIONSOFINTEREST . 36 SOURCESOFSUPPORT . 36 DIFFERENCES -
Medication Other Information Aches and Pains Constipation Cough/Cold Diarrhea Fever Over the Counter Medications in Pregnancy
Over the Counter Medications in Pregnancy Women commonly use over the counter medications in pregnancy. This is a list of those medication you may safely use during pregnancy. If you have any questions about these medications and how to use them please contact your Healthcare Provider's office. Unless otherwise stated please take the medication as directed on the manufactures label. Medication Other Information Aches and Pains * Tylenol Extra Strength 500 mg tablet No more than 6 tablets in a 24 hour period * Tylenol 325 mg tablet No more than 8 in a 24 hour period Constipation Stool Softener Increases the amount of water in your stools to make them easier to pass * Colace (docusate sodium) * Surfak (docusate calcium) * Docusate Fiber Laxative Increases the amount of bulk in your stools to make them easier to pass * Metamucil (psyllium) * Fibercon (Calcium polycarbophil 625 mg) Stool Softener/Fiber Laxative Increases the amount of water in your stools to make them easier to pass * Peri-Colace (docusate sodium/sennosides) * Senekot -S (docusate sodium/sennosides) Osmotic Laxative Increases the amount of water in your stools to make them easier to pass * Milk of Magnesia * MiraLax (polyethylene glycol 3350) Cough/Cold Expectorants Help thin mucus and phlegm so they can be coughed up * Robitussin * Guaifenesin Antihistamines Can be used to relieve seasonal allergy and common cold symptoms of nasal congestion, * Chlorpheniramine sneezing and itchy eyes Cough Suppressants Help calm a cough * Dextromethorphan Decongestants Are used to relieve -
Cycle Stability and Hydration Behavior of Magnesium Oxide and Its Dependence on the Precursor-Related Particle Morphology
nanomaterials Article Cycle Stability and Hydration Behavior of Magnesium Oxide and Its Dependence on the Precursor-Related Particle Morphology Georg Gravogl 1,2, Christian Knoll 2,3 , Jan M. Welch 4, Werner Artner 5, Norbert Freiberger 6, Roland Nilica 6, Elisabeth Eitenberger 7, Gernot Friedbacher 7, Michael Harasek 3 , Andreas Werner 8, Klaudia Hradil 5, Herwig Peterlik 9, Peter Weinberger 2 , Danny Müller 2,* and Ronald Miletich 1 1 Department of Mineralogy and Crystallography, University of Vienna, Althanstraße 14, 1090 Vienna, Austria; [email protected] (G.G.); [email protected] (R.M.) 2 Institute of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] (C.K.); [email protected] (P.W.) 3 Institute of Chemical, Environmental & Biological Engineering, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] 4 Atominstitut, TU Wien, Stadionallee 2, 1020 Vienna, Austria; [email protected] 5 X-ray Center, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] (W.A.); [email protected] (K.H.) 6 RHI-AG, Magnesitstraße 2, 8700 Leoben, Austria; [email protected] (N.F.); [email protected] (R.N.) 7 Institute of Chemical Technologies and Analytics, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] (E.E); [email protected] (G.F.) 8 Institute for Energy Systems and Thermodynamics, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] 9 Faculty of Physics, University of Vienna, Boltzmanngasse 5, 1090 Vienna, Austria; [email protected] * Correspondence: [email protected]; Tel.: +43-1-5880-1163-740 Received: 31 August 2018; Accepted: 2 October 2018; Published: 7 October 2018 Abstract: Thermochemical energy storage is considered as an auspicious method for the recycling of medium-temperature waste heat. -
Impact of a Drugs & Therapeutics Backgrounder on Docusate Utilization
Impact of a Drugs & Therapeutics Backgrounder on Docusate Utilization Darren Pasay, B.Sc.Pharm Drug Stewardship Pharmacist (Central Zone) [email protected] Disclosure I have no actual or potential conflict of interest in relation to this topic or presentation. Drug Stewardship in Alberta Health Services • Drug Stewardship (DS) Team established in 2012 • “The shared responsibility of Drugs & Safety Therapeutics Committee (DTC), prescribers, pharmacy and care units to ensure Sustainability medications are used in a manner that maximizes the effectiveness, safety and sustainability of care for our patients” Effectiveness • Research and project support Drugs & Therapeutics Backgrounders (DTBs) • Frontline staff wanted background and support on DTC/formulary issues1 • One page document, meant to enhance conversations with prescribers • Supported by content experts, based upon DTC directions • Published 6 times/year • Followed by 2 interactive webinars for each edition 1. Pasay Darren K, Chow Sheldon JS, Bresee Lauren C, Guirguis Micheal, Slobodan Jeremy. Assessment of current antimicrobial stewardship policies and resources: a focus group project. Healthcare Infection 2015; 20: 7–15. Docusate • Over-the-counter stool softener • It is clear, based on published peer-reviewed literature, that docusate is ineffective for the prevention or treatment of constipation • Open listed on AHS Provincial Drug Formulary • Limited coverage on Alberta Drug Benefit List (palliative care only) Docusate DTB • Preliminary work o ~ 2 million doses/year dispensed • Influences o Some LTC sites have eliminated o Engrained in practice use already • Part of pharmacy, medicine, nursing curriculums • Order sets, Pre-printed care • What are the costs of? orders (PPCO) o Procurement o Seen as innocuous, safe o Processing, dispensing o Medication administration o Medication burden BOTTOM LINE: Docusate is no more effective than placebo for the prevention and treatment of constipation. -
Disposal of Solid Chemicals in the Normal Trash
Disposal of Solid Chemicals in the Normal Trash Many solid chemicals can be safety discarded into the normal trash, provided they are in containers that are not broken or cracked and have tightly fitting caps. These chemicals are considered acceptable for ordinary disposal because they display none of the properties of hazardous waste, are of low acute toxicity, and have not been identified as having any chronic toxic effects as summarized in the National Institute of Occupational Safety and Health (NIOSH) “Registry of Toxic Effects of Chemical Substances”. Examples of chemicals acceptable for disposal as regular trash are listed below. To dispose of these chemicals, place the containers in a box lined with a plastic bag, tape the top of the box shut, write “Normal Trash” on the box and then place the box next to the lab trash container. Only solid forms of these chemicals can be disposed in this manner. Any questions about these chemicals or other chemicals that may be disposed of in the normal trash should be directed to the Hazardous Materials Technician (610) 330-5225. Chemicals Generally Acceptable for Disposal as Regular Trash Acacia powder, gum Detergent (most) Methyl salicylate Sodium carbonate arabic Cation exchange resins Methylene blue Sodium chloride Acid, Ascorbic Chromatographic Methyl stearate Sodium citrate Acid, Benzoic absorbents Nutrient agar Sodium dodecyl sulfate Acid, Boric Crystal violet Octacosane (SDS) Acid, Casamind Dextrin Parafin Sodium formate Acid, Citric Dextrose Pepsin Sodium iodide Acid, Lactic Diatomaceous -
Barcroft™ Magnesium Hydroxide Powders
TECHNICAL BULLETIN Barcroft™ Magnesium Hydroxide Powders SPI Pharma’s line of magnesium hydroxide powders is available worldwide and These spray dried powders provides the consistent quality required for pharmaceutical use. These powders are specifically designed for are used in wet granulation and direct compression tableting and suspension use in antacid tablets. applications. The products listed are typical of the SPI Pharma magnesium Resuspendible powders are hydroxide powder product line. Products are customized upon request. used for Milk of Magnesia Typical products and properties: (MOM) and antacid suspensions. They are also used in the production of ™ Barcroft Assay Surface Area Comments Product (as Al(OH)3) salts of weak acids, such as magnesium citrate. 5100CG 95-100% 50 m2/g USP, EP, low lead (<125ppb) 5200M 95-100% 65 m2/g USP, EP, resuspendible • meet USP/EP code 5300D 95-100% 45 m2/g USP dense powder (0.7 g/ml) • available in low and high surface area to meet formulation requirements 5100CG is primarily used in wet granulated antacid and laxative tablets. It is free flowing and blends very well with other ingredients. It is low lead (<125 ppb) • products produce very and can be used in antacids that must meet USA’s California Proposition 65. consistent re-hydrated 5200M is a medium-density product specifically designed for rehydration from pourable gels (MOM) the powdered form to produce a smooth, viscous, nonseparating suspension. This is required for milk of magnesia (MOM) laxative systems. Barcroft™ 5200M • spray dried to control is cost-effective for shipment anywhere in the world since it eliminates the cost particle size and density of shipping water. -
Dietary Supplements Compendium Volume 1
2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs . -
Medications and the Gluten-Free Diet
Resources for GF Drug Medications and the Information: Gluten-Free Diet - www.glutenfreedrugs.com (Pharmacist controlled site) Updated January 2021 - dailymed.nlm.nih.gov/ Staying gluten-free involves more than just dietary changes.While use of dailymed/ gluten as an ingredient in medications is uncommon, medications must also be evaluated for their gluten content. Many pharmaceuticals have an additional filler called an excipient, used to make a particular dosage form of the drug. These fillers are often made from corn, potato, or tapioca. However, some are derived This educational bulletin has been from wheat or, rarely, barley. If you have doubts about the gluten-free status of a produced by the Gluten Intolerance medication, it is important that you consult with your pharmacist and/or check with Group of North America, a registered the manufacturer of the product. 501(c)3 organization. Learn more about GIG at www.gluten.org. The majority of drug manufacturers do not clearly label their products or packaging with information regarding the gluten content of their drug. Medications GIG is on a mission to make life easier – whether prescription or over-the-counter - are not included in the FDA gluten- for everyone living gluten-free. free labeling regulation which applies to FDA-regulated food products. In late 2017 the FDA issued a draft document on labeling recommendations for medications; as of May 2018 the guidelines were not finalized. If and when This information is for educational purposes only. Consult your such guidelines are finalized, consumers may have easier access to information healthcare team when considering about the gluten content of medications. -
Estonian Statistics on Medicines 2016 1/41
Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole